
Svetlana Golocorbin-Kon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3760404/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: A Pharmacoinformatic Preliminary Study. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1407-1413.	1.7	3
2	Influence of Bile Acids in Hydrogel Pharmaceutical Formulations on Dissolution Rate and Permeation of Clindamycin Hydrochloride. Gels, 2022, 8, 35.	4.5	4
3	Coping with the burden of the COVID-19 pandemic: a cross-sectional study of community pharmacists from Serbia. BMC Health Services Research, 2021, 21, 304.	2.2	29
4	The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection. Vojnosanitetski Pregled, 2021, 78, 708-715.	0.2	3
5	Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights. European Journal of Drug Metabolism and Pharmacokinetics, 2021, , 1.	1.6	1
6	The role of pharmacists in crisis management and humanitarian missions: Current state and perspectives. PONS - Medicinski Casopis, 2021, 18, 41-52.	0.0	0
7	Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Scientific Reports, 2021, 11, 22123.	3.3	2
8	What Is fishy in asymptomatic patients?: Co-occurrence of Aerococcus urinae infection in pediatric patient with phimosis. Acta Facultatis Medicae Naissensis, 2021, 38, 399-402.	0.4	0
9	DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 1-14.	1.6	13
10	Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 2020, 10, 106.	3.3	41
11	A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi Pharmaceutical Journal, 2020, 28, 165-171.	2.7	17
12	Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies. Scientific Reports, 2020, 10, 7715.	3.3	30
13	Histological effects of pharmacologically active human bile acid nano/micro-particles in Type-1 diabetes. Therapeutic Delivery, 2020, 11, 157-171.	2.2	9
14	Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation. Pharmacological Reports, 2020, 72, 368-378.	3.3	16
15	Internet Marketing of Cardioprotective Dietary Supplements. Journal of Alternative and Complementary Medicine, 2020, 26, 204-211.	2.1	13
16	>Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, inÂPancreatic β-Cells. Nanotechnology, Science and Applications, 2020, Volume 13, 1-9.	4.6	13
17	Modulatory Nano/Micro Effects of Diabetes Development on Pharmacology of Primary and Secondary Bile Acids Concentrations. Current Diabetes Reviews, 2020, 16, 900-909.	1.3	14
18	Pharmacological effects of secondary bile acid microparticles in diabetic murine model. Current Diabetes Reviews, 2020, 16, .	1.3	9

#	Article	IF	CITATIONS
19	Drug sodium intake: Warning in cardiovascular diseases treatment. Hospital Pharmacology, 2020, 7, 913-922.	0.3	2
20	New horizons of methotrexate application. PONS - Medicinski Casopis, 2020, 17, 20-26.	0.0	1
21	Pharmacokinetic and drug absorption profiles of the anti-hyperglycaemic agent gliclazide in oral tissue-targeted microcapsules in rats. Scripta Medica, 2020, 51, 15-20.	0.1	5
22	Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. Pharmacological Research, 2019, 146, 104333.	7.1	27
23	Bile acid-polymer-probucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model. Pharmaceutical Development and Technology, 2019, 24, 1272-1277.	2.4	11
24	Environmental Transformation of Pharmaceutical Formulations: A Scientific Review. Archives of Environmental Contamination and Toxicology, 2019, 77, 155-161.	4.1	18
25	An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques. PLoS ONE, 2019, 14, e0214984.	2.5	12
26	Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment. Therapeutic Delivery, 2019, 10, 99-106.	2.2	19
27	Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Therapeutic Delivery, 2019, 10, 563-571.	2.2	12
28	Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids. Therapeutic Delivery, 2019, 10, 573-583.	2.2	12
29	In silico Discovery of Resveratrol Analogues as Potential Agents in Treatment of Metabolic Disorders. Current Pharmaceutical Design, 2019, 25, 3776-3783.	1.9	7
30	The effect of magnesium stearate and sodium starch glycolate on powder flowability. Acta Periodica Technologica, 2019, , 304-310.	0.2	4
31	The significance of dosage forms for pharmacovigilance in the case of topical corticosteroids. Hospital Pharmacology, 2019, 6, 800-806.	0.3	3
32	Consumption and pharmaceutical-technological formulations of herbal medicines in Serbia. Timocki Medicinski Glasnik, 2019, 44, 56-62.	0.0	0
33	Botulinum toxin: Poison and medicine. PONS - Medicinski Casopis, 2019, 16, 24-31.	0.0	0
34	Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 269-280.	1.6	23
35	Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid. Therapeutic Delivery, 2018, 9, 811-821.	2.2	21
36	Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 748-754.	2.8	28

#	Article	IF	CITATIONS
37	Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. Frontiers in Pharmacology, 2018, 9, 1283.	3.5	159
38	Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. Frontiers in Pharmacology, 2018, 9, 1382.	3.5	78
39	Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 741-747.	2.8	22
40	Dried blood spot: Utilizing dry blood for pharmacokinetic investigations - an old method with great future for therapeutic drug monitoring. Vojnosanitetski Pregled, 2018, 75, 1222-1225.	0.2	2
41	Experimental and chemometric study of antioxidant capacity of basil (Ocimum basilicum) extracts. Industrial Crops and Products, 2017, 100, 176-182.	5.2	37
42	Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects. European Journal of Pharmaceutical Sciences, 2017, 106, 1-9.	4.0	17
43	The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 881-890.	1.6	9
44	High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 1005-1011.	1.6	8
45	Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes. Journal of Diabetes, 2016, 8, 238-245.	1.8	7
46	The Effect of Diabetes and Hypertension on the Placental Permeation of the Hydrophilic Drug, Ranitidine. Placenta, 2016, 48, 144-150.	1.5	4
47	Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1290-1297.	2.8	49
48	An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharmaceutical Development and Technology, 2015, 20, 702-709.	2.4	56
49	Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. Journal of Microencapsulation, 2015, 32, 151-156.	2.8	38
50	Reasons for and frequency of off - label drug use. Medicinski Pregled, 2015, 68, 35-40.	0.1	22
51	Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Design, Development and Therapy, 2014, 8, 1221.	4.3	32
52	Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Design, Development and Therapy, 2014, 8, 1003.	4.3	30
53	Interaction Between Different Extracts of Hypericum perforatum L. from Serbia and Pentobarbital, Diazepam and Paracetamol. Molecules, 2014, 19, 3869-3882.	3.8	8
54	Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. Journal of Pharmaceutical Innovation, 2014, 9, 150-157.	2.4	58

#	Article	IF	CITATIONS
55	Application of bile acids in drug formulation and delivery. Frontiers in Life Science: Frontiers of Interdisciplinary Research in the Life Sciences, 2013, 7, 112-122.	1.1	100
56	Effects of occupational exposure to pesticides and consumption of alcoholic beverages on liver functions. Zdravstvena Zastita, 2013, 42, 47-55.	0.2	1
57	An Insight on Differences in Availability and Reimbursement of Orphan Medicines Among Serbia, Bulgaria and Sweden. Biotechnology and Biotechnological Equipment, 2012, 26, 3236-3241.	1.3	15
58	Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 99-108.	1.6	41
59	Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations. Drugs in R and D, 2011, 11, 53-60.	2.2	5
60	The influence of probiotics on the cervical malignancy diagnostics quality. Vojnosanitetski Pregled, 2011, 68, 956-960.	0.2	11
61	Hypoglycemic effect of herbicide 2,4-dichlorophenoxyacetic acid (2,4-D). Pesticidi I Fitomedicina = Pesticides and Phytomedicine, 2010, 25, 349-352.	0.2	3
62	Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. European Journal of Drug Metabolism and Pharmacokinetics, 2009, 34, 93-99.	1.6	28
63	The influence of 3α,7α-dihydroxy-12-keto-5β-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 137-142.	1.6	42